A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 85
- Registration Number
- NCT05244551
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Yuan LU, Shanghai, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515, China
🇨🇳Chongqing Daping Hospital, Chongqing, Chongqing, China
A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 24
- Registration Number
- NCT05103917
- Locations
- 🇨🇳
Shang hai Tumor Hospital, Shanghai, Shang Hai, China
A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05086666
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
- Conditions
- Neoplasms
- Interventions
- Drug: ABSK043 oral capsule
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT04964375
- Locations
- 🇦🇺
Sydney South West Private Hospital, Liverpool, Australia
🇦🇺Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇦🇺Icon Cancer Centre South Brisbane, Brisbane, Queensland, Australia
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor
- Conditions
- Advanced Liver Cancer
- Interventions
- Drug: 320 mg ABSK-011capsuleDrug: 60mg ABSK-011capsuleDrug: 120mg ABSK-011capsuleDrug: 180mg ABSK-011capsuleDrug: 240mg ABSK-011capsuleDrug: 400mg ABSK-011capsule
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT04906434
- Locations
- 🇨🇳
National Taiwan University Hospital, Taibei, China
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Abbisko Therapeutics Co, Ltd
- Target Recruit Count
- 85
- Registration Number
- NCT04192344
- Locations
- 🇨🇳
Huashan Hospital of Fudan University, Shanghai, Shanghai, China
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China